{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:54:24Z","timestamp":1783727664180,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Antibody-mediated rejection (AMR) following orthotopic heart transplant (OHT) causes significant morbidity and mortality. There are limited data on antibodies to the angiotensin II type 1 receptor antibody (AT1R-Ab) causing rejection following OHT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This is a retrospective, single-center study that presents our 2-y experience with a series of 11 patients with evidence of nonspecific graft dysfunction and pathologic levels of AT1R-Ab. The clinical outcomes and treatments were compared to a group of 10 patients, also with evidence of nonspecific graft dysfunction, but who had nonsignificant AT1R-Ab titers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The mean age of the AT1R-Ab cohort was 52% and 73% were bridged to transplant with an left ventricular assist device. The average left ventricular ejection fraction at presentation was 45%, and most were not on an angiotensin receptor blocker (ARB). Endomyocardial biopsies in those with elevated AT1R-Ab levels frequently showed reactive endothelium\/endocardium without C4d or intravascular CD68 staining. Ten patients (91%) were started on an ARB. Other therapies included plasmapheresis and IVIg (64%), with 4 patients also receiving rituximab. Most patients had symptom improvement, but minimal change in graft function at an average 6 mo of follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The role of AT1R-Ab-mediated rejection in OHT recipients remains poorly understood. More than half of patients at our center who presented with graft dysfunction in the absence of acute cellular rejection or AMR were found to have elevated AT1R-Ab titers. Empiric AMR treatment in conjunction with ARB therapy may improve patient outcomes. Future studies are needed to better define the optimal treatment modalities for ATR1-Ab-mediated AMR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003712","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T09:30:36Z","timestamp":1614763836000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Angiotensin II Type 1 Receptor Antibody-mediated Rejection Following Orthotopic Heart Transplant: A Single-center Experience"],"prefix":"10.1097","volume":"106","author":[{"given":"Jonathan D.","family":"Moreno","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Kopecky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Dehner","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kostelecky","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Vader","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Schilling","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO."},{"name":"Department of Pathology & Immunology, Washington University in St. Louis, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.healun.2018.01.1291","article-title":"The management of antibodies in heart transplantation: an ISHLT consensus document.","volume":"37","author":"Kobashigawa","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.healun.2016.10.016","article-title":"Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.","volume":"36","author":"Clerkin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOT.0000000000000335","article-title":"Non-HLA antibodies in transplantation: when do they matter?","volume":"21","author":"Philogene","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.humimm.2019.04.012","article-title":"Antibodies against angiotensin II type 1 and endothelin A receptors: relevance and pathogenicity.","volume":"80","author":"Philogene","year":"2019","journal-title":"Hum Immunol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/hy1201.100589","article-title":"Role of the renin-angiotensin system in vascular diseases: expanding the field.","volume":"38","author":"Ruiz-Ortega","year":"2001","journal-title":"Hypertension"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2003.11.060","article-title":"Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease.","volume":"43","author":"Yousufuddin","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.TP.0000436927.08026.a8","article-title":"Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.","volume":"97","author":"Reinsmoen","year":"2014","journal-title":"Transplantation"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1172\/JCI4106","article-title":"Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.","volume":"103","author":"Wallukat","year":"1999","journal-title":"J Clin Invest"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.","volume":"352","author":"Dragun","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/TP.0b013e3181fd97f1","article-title":"Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.","volume":"90","author":"Reinsmoen","year":"2010","journal-title":"Transplantation"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/TP.0000000000000185","article-title":"Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal.","volume":"98","author":"Ohe","year":"2014","journal-title":"Transplantation"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/ajt.15564","article-title":"Hyperacute graft dysfunction in an orthotopic heart transplant in the presence of non-HLA antibodies.","volume":"20","author":"Villa","year":"2020","journal-title":"Am J Transplant"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/ajt.14053","article-title":"Immediate and catastrophic antibody-mediated rejection in a lung transplant recipient with anti-angiotensin II receptor type 1 and anti-endothelin-1 receptor type A antibodies.","volume":"17","author":"Cozzi","year":"2017","journal-title":"Am J Transplant"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/TP.0b013e3182692ad2","article-title":"Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation.","volume":"94","author":"Hiemann","year":"2012","journal-title":"Transplantation"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/icvts\/ivv344","article-title":"The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.","volume":"22","author":"Urban","year":"2016","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/ajt.12397","article-title":"Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.","volume":"13","author":"Giral","year":"2013","journal-title":"Am J Transplant"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12395","article-title":"Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.","volume":"13","author":"Taniguchi","year":"2013","journal-title":"Am J Transplant"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/tri.12371","article-title":"The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.","volume":"27","author":"Banasik","year":"2014","journal-title":"Transpl Int"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1111\/ctr.13178","article-title":"Revealing a new mode of sensitization induced by mechanical circulatory support devices: impact of anti-AT1 R antibodies.","volume":"32","author":"Zhang","year":"2018","journal-title":"Clin Transplant"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.humimm.2018.02.001","article-title":"Pre-transplant screening for non-HLA antibodies: who should be tested?","volume":"79","author":"Philogene","year":"2018","journal-title":"Hum Immunol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/TP.0b013e31816f612a","article-title":"Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies.","volume":"85","author":"Amico","year":"2008","journal-title":"Transplantation"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/TP.0b013e318234b337","article-title":"Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II.","volume":"92","author":"Kelsch","year":"2011","journal-title":"Transplantation"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cardfail.2020.06.010","article-title":"Elevated AT1R antibody and morbidity in patients bridged to heart transplant using continuous flow left ventricular assist devices.","volume":"26","author":"Chau","year":"2020","journal-title":"J Card Fail"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jca.21657","article-title":"Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.","volume":"33","author":"Yamada","year":"2018","journal-title":"J Clin Apher"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.humimm.2016.08.009","article-title":"Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan.","volume":"77","author":"Carroll","year":"2016","journal-title":"Hum Immunol"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jss.2005.07.011","article-title":"The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.","volume":"132","author":"Yamamoto","year":"2006","journal-title":"J Surg Res"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00395-004-0489-0","article-title":"The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.","volume":"100","author":"Yamamoto","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1053-2498(00)00197-2","article-title":"New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.","volume":"19","author":"Richter","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.phrs.2017.06.013","article-title":"Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism.","volume":"123","author":"Takezako","year":"2017","journal-title":"Pharmacol Res"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2741\/4698","article-title":"Antibodies against GPCR.","volume":"23","author":"Meyer","year":"2018","journal-title":"Front Biosci (Landmark Ed)"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:11:52Z","timestamp":1749312712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003712","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}